Journal
CURRENT ALLERGY AND ASTHMA REPORTS
Volume 14, Issue 9, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11882-014-0462-4
Keywords
Review; Autoimmune lymphoproliferative syndrome (ALPS); Apoptosis; Autoimmunity; Primary immunodeficiency
Categories
Funding
- Intramural Research Program of the National Institute of Allergy and Infectious Diseases
- [1R03AR059286]
Ask authors/readers for more resources
Autoimmune lymphoproliferative syndrome (ALPS) is characterized by immune dysregulation due to a defect in lymphocyte apoptosis. The clinical manifestations may be noted in multiple family members and include lymphadenopathy, splenomegaly, increased risk of lymphoma, and autoimmune disease, which typically involves hematopoietic cell lines manifesting as multilineage cytopenias. Since the disease was first characterized in the early 1990s, there have been many advances in the diagnosis and management of this syndrome. The inherited genetic defect of many ALPS patients has involved (FAS) pathway signaling proteins, but there remain those patients who carry undefined genetic defects. Despite ALPS having historically been considered a primary immune defect presenting in early childhood, adult onset presentation is increasingly becoming recognized and more so in genetically undefined patients and those with somatic FAS mutations. Thus, future research may identify novel pathways and/or regulatory proteins important in lymphocyte activation and apoptosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available